ORI Capital

Established in 2015, ORI Capital is a Hong Kong-based venture capital firm specializing in early-stage investments in the biotechnology and healthcare sectors. The firm focuses on innovative companies involved in diagnostics, drug delivery, and therapeutics, particularly targeting diseases with high mortality rates such as cancer, cardiovascular, and neurodegenerative diseases. ORI Capital aims to blend scientific innovation with financial acumen to support ventures that have the potential to make a significant impact on global health.

The firm's investment strategy emphasizes a global approach, seeking opportunities in various regions including China, the United States, Europe, and other key markets. ORI Capital's portfolio includes companies like Semma Therapeutics, Kymab, Orchard Therapeutics, TriSalus Life Sciences, and CG Oncology, reflecting its commitment to advancing transformative healthcare solutions. The firm is also exploring the integration of artificial intelligence to enhance its investment processes and identify promising biotech innovations.

ORI Capital's leadership includes founder and senior partner Simone Song, who has been instrumental in shaping the firm's vision and growth. The firm is headquartered in Hong Kong, with contact information available through its official website. ORI Capital continues to seek investments that align with its mission to support groundbreaking healthcare innovations and improve patient outcomes worldwide.